Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(40.0%)
Phase 1
1(20.0%)
Phase 3
1(20.0%)
Phase 4
1(20.0%)
5Total
N/A(2)
Phase 1(1)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05681065Not ApplicableCompleted

Affective Based Integrated Care for Better Quality of Life.Pilot Implementation. Site1: Primary Care Madrid, Spain.

Role: collaborator

NCT01261234Not ApplicableCompleted

Carotid Artery Stenting With Cilostazol Addition for Restenosis

Role: collaborator

NCT00333164Phase 3Completed

Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis

Role: collaborator

NCT00221182Phase 1Terminated

Stem Cell Study for Patients With Heart Disease

Role: lead

NCT00665886Phase 4Completed

Compact Closed System Versus Mounted Open System (COSMOS)

Role: collaborator

All 5 trials loaded